Navigation Links
BioMarin Announces Third Quarter 2010 Financial Results
Date:10/28/2010

ensation expense8.910.025.727.734.537.0Upfront license fees

(1)--8.8-8.8-Impairment charges

(2)--5.9-5.9-Net gain on the sale of equity investments--(1.6)(1.0)(1.6)(1.0)Acquisition expenses

(3)1.81.8-2.0Tax benefit

(4)-(223.1)(223.1)-(223.0)Income tax effect of Non-GAAP adjustments

(5)-0.3---Non-GAAP net income $

15.5$

6.0$

33.9$

23.4$

47.1$

28.0 to 33.0Notes: (1)  Represents upfront license payments related to our collaboration agreement with La Jolla Pharmaceutical Company in the first quarter of 2009.   (2)  Includes impairment losses on investments in Summit plc. and La Jolla Pharmaceutical Company recognized during the first quarter of 2009.(3)  Represents transactions costs associated with the acquisition of ZyStor Therapeutics Inc., during the third quarter of 2010.   (4)  Represents the release of the Company's income tax valuation allowance during the third quarter of 2010.(5)  Represents the tax effect of the adjustments.   BioMarin believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP information because it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.

Diluted Earnings Per Share Calculation For the third quarter of 2010, the nine months ended September 30, 2010 and the full year forecast for the year ending 20
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Host a Research and Development Day on October 19th
2. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
5. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
6. BioMarin Acquires ZyStor Therapeutics, Inc.
7. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
8. BioMarin to Acquire LEAD Therapeutics
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2009 Financial Results
11. BioMarin to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Conn.--(BUSINESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN) ... studies for NG2-73, the Company's lead compound,for the ... SLEEP,2007 Annual Meeting of the Associated Professional Sleep ... studies,with NG2-73 in chronic insomnia patients are currently ...
... offers five questions to help women,learn about breast cancer ... – According to a new,GfK Roper Public Affairs survey ... the majority (76,percent) of women surveyed said they know ... unaware of the important recent,progress made in treatment. Fewer ...
Cached Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... 11, 2014 Global enterprises today are ... outsource day-to-day management activities. Managed services offer these global ... The economic slowdown resulted into rising operational costs to ... is considered to be the global market driver for ... The global managed services market is estimated to grow ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... PROVIDENCE, R.I. -- Researchers from The Miriam ... under age 65 have significantly higher rates of ... with mobility impairments were less likely to attempt ... quit-smoking treatments may not be sufficient for this ... online in advance of print in the ...
(Date:7/11/2014)... kind has found that organic foods and crops ... counterparts, including more antioxidants and fewer, less frequent ... unprecedented 343 peer-reviewed publications comparing the nutritional quality ... including fruits, vegetables, and grains. The study team ... organic and non-organic foods. , "Science marches ...
Breaking Medicine News(10 mins):Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... INDIANAPOLIS Technologies for rapid detection of bacterial ... supply. Researchers from the School of ... the Bindley Bioscience Center at Purdue University have ... classification of harmful bacteria in food. The investigators ...
... in the Oct. 15 issue of the Journal of ... a much higher prevalence and risk of restless legs syndrome ... may improve sleep and quality of life in people with ... syndrome was about 10 times higher in the fibromyalgia group ...
... prodigious precursors of all the tissues in our body, ... unfortunately, cancer. Now research from Rockefeller University shows that ... live for too long, can increase the odds of ... cell death in precursor cells for blood, or hematopoietic ...
... a class of drugs known as beta blockers have been ... by decreasing the cardiac workload and oxygen demand on the ... Heart Journal , Northwestern Medicine cardiologist Jeffrey J. Goldberger found ... enough dose of these drugs, which can put their recovery ...
... Reporter , THURSDAY, Oct. 14 (HealthDay News) -- Only one ... recommended colon cancer screening guidelines, a new report finds. ... while the remaining 40 percent don,t follow guidelines for any ... to be done to understand how to improve colorectal cancer ...
... Two years ago, a study by University of North ... drug called ondansetron helps reduce vomiting, the need for ... gastroenteritis. Now a new economic analysis led by ... assistant professor of pediatrics at UNC, concludes that routinely ...
Cached Medicine News:Health News:Eat safer: Novel approach detects unknown food pathogens 2Health News:Study finds a high rate of restless legs syndrome in adults with fibromyalgia 2Health News:Gene identified that prevents stem cells from turning cancerous 2Health News:Gene identified that prevents stem cells from turning cancerous 3Health News:Low beta blocker dose can put patients at risk for subsequent heart attacks 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 2Health News:Most Doctors Don't Follow Colon Cancer Screening Guidelines 3Health News:Anti-vomiting drug could prevent thousands of hospitalizations, save millions of dollars 2
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Laser System features a patented technique for ... It selectively targets pigmented cells and increases ... II is equipped with a Q-switch that ... which induces the same cell replacement mechanism ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: